Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients (GemSign-01)
Cancer Of Pancreas
About this trial
This is an interventional other trial for Cancer Of Pancreas
Eligibility Criteria
Inclusion Criteria: Metastatic pancreatic adenocarcinoma histological proved FOLFIRINOX chemotherapy-ineligible patient and going to receive first-line metastatic chemotherapy with gemcitabine monotherapy Tumor material allowing assessment of GEMCore status (i.e. FFPE block with tumor cellularity ≥ 10%); Life expectancy > 2 months; Measurable target according to RECIST 1.1 criteria; No previous treatment in metastatic situation; Age ≥ 18 years; Patient not opposed to study participation; Affiliation to a social security system, or beneficiary of such a scheme. Exclusion Criteria: Contraindication to Gemcitabine treatment; ECOG performance status ≥ 3; Person in emergency situation or unable to express non-opposition; Patient under a legal protection measure (adult under guardianship, curatorship or safeguard of justice); Unable to undergo medical follow-up for geographical, social or psychological reasons.
Sites / Locations
Arms of the Study
Arm 1
Experimental
metastatic pancreatic adenocarcinoma patients
Analyze of GemCore status